High Court dismissal may trigger revised Bengaluru improvement charges
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
AstraZeneca Pharma India expects a revised demand from Bengaluru North City Corporation or Greater Bengaluru Authority after the Karnataka High Court dismissed the company's appeal. The demand may seek improvement charges of up to INR 70.8 million, plus interest. No amount has been paid. The company has set aside an additional INR 156.1 million in its accounts and will review the demand before taking action.
Possible cash outflow is up to INR 70.8 million plus interest. AstraZeneca has set aside INR 156.1 million, but the final cost is uncertain.